1. No category

Nye antistoffer fra
august 2014
De nyeste antistoffer
Antistof
Klon
Anvendelse
Format,
Produktnr. koncentreret
MUC-4
8G7
Pancreascarcinom/normalt pancreasvæv
406M
0,1; 0,5; 1,0 ml
EZH2
11
T-celle lymfom
415M
0,1; 0,5; 1,0 ml
EGFR
SP84
Bryst carcinom
414M
0,1; 0,5; 1,0 ml
GLUT3
Polyklonalt
Germ tumor celler
413A
0,1; 0,5; 1,0 ml
Se detaljerede beskrivelser på de følgende sider.
Nyere antistoffer
Format,
Produktnr. koncentreret
Antistof
Klon
Anvendelse
Caveolin-1
2297
Differentiering ml. epithelioid mestheliom og
adenocarcinom
412M
0,1; 0,5; 1,0 ml
Cytokeratin
(CAM5.2)
Hepartocellulært neoplasme
452M
0,1; 0,5; 1,0 ml
Cytokeratin
10
EP97
Planocellulært carcinom
4210R
0,1; 0,5; 1,0 ml
GATA3
L50-823
Lobulær bryst carcinom og
invasive duktale carcimoner
390M
0,1; 0,5; 1,0 ml
Heat Shock
Protein 27
G3.1
Cervical pladeepithel carcimon og
highgraded dyplasi
398M
0,1; 0,5; 1,0 ml
TFE 3
MRQ-37
Pædiatrisk renal cellecarcinom
354R
0,1; 0,5; 1,0 ml
BOB.1
SP92
NHPHL/CHL
294R
0,1; 0,5; 1,0 ml
TLE1
1F5
Synovial sarcom
401M
0,1; 0,5; 1,0 ml
Treponema
pallidum
Polyklonalt
Syfillis
397A
0,1; 0,5; 1,0 ml
HSV1
10A3
HSV
361M
0,1; 0,5; 1,0 ml
Nestin
10C2
Desmoplastisk melanom
388M
0,1; 0,5; 1,0 ml
ER
EP1
Østrogen receptor
249R
0,1; 0,5; 1,0 ml
ALDH1A1
44
Solitært fibromatøs tumor
400M
0,1; 0,5; 1,0 ml
Cathepsin K
3F9
Translocation renal cellecarcimon
402M
0,1; 0,5; 1,0 ml
SALL4
6E3
Pan germinal cellemarkør
385M
0,1; 0,5; 1,0 ml
OLIG2
211F1.1
Gliomer
387M
0,1; 0,5; 1,0 ml
Adenovirus
20/11 & 2/6
CMV/HSV
212M
0,1; 0,5; 1,0 ml
Adipophilin
Polyklonalt
Sebaceous neoplasme
393A
0,1; 0,5; 1,0 ml
TIA-1
EP243
Cytotoksisk T-celle lymfom og NK lymfom
381R
0,1; 0,5; 1,0 ml
Stathmin
SP49
Differentiering mellem high og low CIN
394R
0,1; 0,5; 1,0 ml
Langerin
12D6
Differentiering mellem langerhanske celler og
dendritiske tumorceller
392M
0,1; 0,5; 1,0 ml
3
Glutamine
Synthease
GS-6
Maligne hepatocytter
389M
0,1; 0,5; 1,0 ml
MyoD1
EP212
Rhabdomyosarkomer
386R
0,1; 0,5; 1,0 ml
Cadherin-17
SP183
Differentiering mellem carcinom og GI
378R
0,1; 0,5; 1,0 ml
CD13
SP 187
Differentiering mellem AMML og andre AML-er
113R
0,1; 0,5; 1,0 ml
CD16
SP 175
Differentiering mellem NK celle leukæmi og andre
leukæmier
116R
0,1; 0,5; 1,0 ml
Alle antistoffer har tre års holdbarhed og er IVD-godkendte.
Kontakt
Gitte Blach Skeldrup
Stephan Nandrup-Buus
Nordic Application Manager
IHC, FISH/CISH & patologi
Product Specialist
Immunologi
gbs@ahdiagnostics.dk
8745 9040
snb@ahdiagnostics.dk
8745 9043
AH diagnostics as • Runetoften 18 • DK-8210 Aarhus V • Tel.: +45 8745 9010 • Fax: +45 8745 1292 • www.ahdiagnostics.dk
AH diagnostics AB • Gårdsvägen 2, 1 tr • SE-169 70 • Solna • Tel.: +46 (0)8 680 0845 • Fax: +46 (0)8 680 0435 • www.ahdiagnostics.se
AH diagnostics Oy • Viikinkaari 4 • FI-00790 Helsinki • Tel.: +358 (0)10 325 3000 • Fax: +358 (0)10 325 3010 • www.ahdiagnostics.fi
AH diagnostics as • Fjellgata 1 • NO-0566 Oslo • Tel.: +47 2323 3260 • Fax: +47 2323 3270 • www.ahdiagnostics.no
4
MUC4 (8G7)
Mucin 4 (MUC4) is a transmembranous glycoprotein. MUC4 is
expressed in the cytoplasm of certain epithelial surfaces, such
as colonic, breast, and lung epithelia. An abnormal expression
of MUC4 has been reported in various carcinomas of the colon, pancreas, breast, and ovaries. MUC4 is highly expressed
in the vast majority of human pancreatic neoplasms, such as
intraductal papillary mucinous neoplasia of the pancreas, pancreatic intraepithelial neoplasms and pancreatic ductal adenocarcinoma; however, it is not detected in the normal pancreas
or in chronic pancreatitis. MUC4 is not expressed in normal
bile ducts, but it can be overexpressed in intrahepatic cholangiocarcinoma and bile duct cholangiocarcinoma. MUC4 overexpression has been reported in low-grade fibromyxoid sarcoma
(LGFMS).
Specifications
In this study a large cohort of LGFMS, all with FUS gene rearrangement confirmed by FISH, showed cytoplasmic staining
for MUC4, usually in a strong and diffuse manner. Similarly,
strong, diffuse cytoplasmic staining for MUC4 was identified in
78% (32/41) of cases of sclerosing epithelioid fibrosarcoma.
MUC4 expression is also detected in the glandular component
of biphasic synovial sarcomas (90%). Focal staining, usually interpreted as only scattered cells, was also seen in a subset of
ossifying fibromyxoid tumors (29%), epithelioid GISTs (20%)
and myoepithelial carcinomas (10%); whereas all other epithelioid soft tissue tumors— including clear cell sarcoma, epithelioid sarcoma, epithelioid hemangiosarcoma, PEComa and
melanoma— were negative. It should be noted that various carcinomas may express MUC4, and therefore additional keratins
or lineage-specific markers may be needed to exclude this possibility in some cases.
SKU
MUC4 (8G7)
Species
Mouse monoclonal
406M-14
0.1 ml, concentrate
Visualization
Cytoplasmic
406M-15
0.5 ml, concentrate
Reactivity
Paraffin
406M-16
1.0 ml, concentrate
Isotype
IgG1/k
406M-17
1 ml, predilute
Dilution
1:10-1:50*
406M-18
7 ml, predilute
Controls
Pancreatic ductal adenocarcinoma,
colon, colorectal adenocarcinoma
406S
5 Positive control slides
Labeling
designation
IVD
This antibody is also commonly used with these other antibodies:
CA19-9 (121SLE)
MUC2 (MRQ-18)
MUC5AC (MRQ-19)
S100P (16/f5)
5
EZH2 (11)
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a
methylation epigenetic mark at lysine 27 residue of histone H3
(H3K27me3) in order to silence gene expression. EZH2 target
genes are involved in a variety of biological processes such as
stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is frequently overexpressed in many cancer
types. Hyperactivation of EZH2, either by overexpression or
mutations, is found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition
to melanoma. EZH2 overexpression has been reported in nonsmall cell lung cancers and lymphoma. The EZH2 protein is
rarely detected in normal breast duct epithelium and in normal
and hyperplastic lymph node. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells or NK/T cells.
Specifications
However, its expression can be seen in most B-cell and T-cell
lymphomas, although only in 20% (1/5) of small lymphocytic
lymphoma and 14% (1/7) of plasma cell myeloma. Plasmacytoma, lymphoplasmacytic lymphoma, and MALT lymphoma
have not been shown to express this protein. Recent studies
also have demonstrated EZH2 is aberrantly over-expressed in
pediatric rhabdomyosarcoma, independent of the histological
subtypes. In summary, EZH2 correlates with tumor proliferation and may be used in an antibody panel to differentiate
proliferative/aggressive lymphoma variants from indolent ones
and normal resting cell populations.
SKU
EZH2 (11)
Species
Mouse monoclonal
415M-14
0.1 ml, concentrate
Visualization
Nuclear
415M-15
0.5 ml, concentrate
Reactivity
Paraffin
415M-16
1.0 ml, concentrate
Isotype
IgG1
415M-17
1 ml, predilute
Dilution
1:25-1:100*
415M-18
7 ml, predilute
Controls
Prostate adenocarcinoma, tonsil, breast
carcinoma
415S
5 Positive control slides
Labeling
designation
IVD
This antibody is also commonly used with these other antibodies:
E-cadherin (EP700Y)
6
Estrogen Receptor (EP1)
GATA3 (L50-823)
Progesterone Receptor (Y85)
EGFR (SP84)
EGFR is a 170-kDa transmembrane glycoprotein encoded by
the HER-1 proto-oncogene located at 7p11.2-p12.1-2, EGFR is
widely expressed on the surface of epithelial cells, fibroblasts,
gliocytes, keratinocytes, and other cell types.
EGFR is overexpressed in many epithelial malignancies including carcinomas of the colorectum, stomach, esophagus,
pancreas, oropharynx, adrenocortical carcinoma, non-small
cell carcinoma of the lung, cutaneous and anal squamous
carcinoma, and head and neck squamous carcinoma. EGFR
protein expression has also been a common finding in breast
carcinoma, particularly in triple-negative, basal-like breast carcinomas. Studies suggest that EGFR expression is not unique
to carcinomas and may be present in malignant bone and soft
tissue tumors.
Specifications
Soft tissue sarcomas such as synovial sarcoma and epithelioid
sarcoma show morphologic and immunophenotypic features
of epithelial differentiation. Hence, EGFR overexpression is
often seen in synovial sarcoma and epithelioid sarcoma. IHC
analysis of 48 synovial sarcoma specimens representing primary and metastatic lesions using the anti-EGFR antibody demonstrated positive reactions in 34 of 48 cases (71%). The same
study included 32 cases of malignant peripheral nerve sheath
tumor, in which EGFR overexpression was found in 20 cases
(62.5%). Cascio, MJ et al. found 13 of 15 cases (87%) of epithelioid sarcoma displayed immunoreactivity of EGFR by IHC.
Findings included strong, homogenous staining in the majority
of cases, but absence of either gene amplification or kinase
domain mutations.
SKU
EGFR (SP84)
Species
Rabbit monoclonal
414R-14
0.1 ml, concentrate
Visualization
Cytoplasmic, membranous
414R-15
0.5 ml, concentrate
Reactivity
Paraffin
414R-16
1.0 ml, concentrate
Isotype
IgG
414R-17
1 ml, predilute
Dilution
1:10-1:50*
414R-18
7 ml, predilute
Control
Breast carcinoma
414S
5 Positive control slides
Labeling
designation
IVD
This antibody is also commonly used with these other antibodies:
Cytokeratin 5 (EP1601Y)
+ Cytokeratin 14 (LL002)
Estrogen Receptor (SP1)
Nestin (10C2)
Progesterone Receptor
(SP42)
7
GLUT3 (polyclonal)
Glucose transporter membrane 3 (GLUT3) is known as a solute carrier family 2 (facilitated glucose transporter) member 3
and represents a membrane bound glucose transporter.
In one study scientists, using immunoprecipitation and western
blot technologies, detected GLUT3 expression in spermatozoa
of testis and brain but not in other types of tissue. In-house
research via immunohistochemistry confirmed GLUT3 expression in testis/spermatozoa, but no GLUT3 was detected
in brain. In a study conducted by Howitt BE et. al. anti-GLUT3
demonstrated membranous staining of seminoma cells in 44
cases (65%) of total 67 specimens.
Specifications
In addition, anti-GLUT3 labeled embryonal carcinoma (20/20)
and yolk sac tumor (8/8) with 100% sensitivity. GLUT3 is not
expressed in non-germ cell tumors such as leydig cell tumor
and adenomatoid tumor. Spermatocytic seminoma, choriocarcinoma, and immature teratoma are also negative for GLUT3.
Therefore, anti-GLUT3 is a very useful IHC marker to include in
a panel for identification of germ cell tumors.
SKU
GLUT3 (polyclonal)
Species
Rabbit polyclonal
413A-14
0.1 ml, concentrate
Visualization
Membranous
413A-15
0.5 ml, concentrate
Reactivity
Paraffin
413A-16
1.0 ml, concentrate
Isotype
N/A
413A-17
1 ml, predilute
Dilution
1:25-1:100*
413A-18
7 ml, predilute
Controls
Embryonal carcinoma, yolk sac tumor
413S
5 Positive control slides
Labeling
designation
IVD
This antibody is also commonly used with these other antibodies:
hCG (polyclonal)
8
Oct-4 (MRQ-10)
PLAP (NB10)
SALL4 (6E3)